Related Experiment Videos
[Diltiazem and modulation of platelet aggregation].
G Colica1, D Salnitro, F Scopelliti
1Divisione di Medicina, Ospedale E. Morelli, Reggio Calabria.
Minerva Cardioangiologica
|January 1, 1990
Summary
Diltiazem, a calcium channel blocker, effectively inhibits adenosine diphosphate (ADP)-induced platelet aggregation. This cardiovascular drug dilates coronary arteries, proving beneficial for treating heart conditions.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Hematology
Context:
- Calcium antagonists are known to affect platelet function.
- Adenosine diphosphate (ADP) is a key mediator of platelet aggregation.
- Cardiovascular diseases remain a leading cause of mortality worldwide.
Purpose:
- To investigate the anti-aggregant properties of Diltiazem.
- To quantify the effect of oral Diltiazem on platelet aggregation in healthy subjects.
Summary:
- A study assessed platelet aggregation in 20 healthy individuals before and after a week of daily 240 mg oral Diltiazem.
- Aggregation curves demonstrated Diltiazem's significant inhibition of ADP-induced platelet aggregation.
- Results confirm Diltiazem's anti-platelet activity.
Impact:
- Diltiazem exhibits anti-aggregant properties, suggesting its therapeutic potential in managing cardiovascular diseases.
- The drug's dual action of coronary vasodilation and platelet inhibition enhances its cardiovascular benefits.